Molecular signaling blockade as a new approach to inhibit leukocyte-endothelial interactions for inflammatory bowel disease treatment

Cell Adhesion and Migration

Volumn 3, Issue 3, 2009, Pages 296-299

  Scaldaferri, Franco ^a   Correale, Carmen ^b   Gasbarrini, Antonio ^a   Danese, Silvio ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Inflammation; Inflammatory bowel disease; Intestinal mucosal endothelium; Intestinal mucosal fibroblasts; Leukocytes adhesion and migration; MAPK; MAPK inhibitors

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; COLLAGENASE; CYCLOOXYGENASE 2; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; SEMAPIMOD; VASCULAR CELL ADHESION MOLECULE 1;

CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; ENDOTHELIUM; ENTERITIS; FIBROBLAST; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTESTINE MUCOSA; LEUKOCYTE; NOTE; PATHOGENESIS;

EID: 68249131563     PISSN: 19336918     EISSN: 19336926     Source Type: Journal    
DOI: 10.4161/cam.3.3.9152     Document Type: Note

References (22)

1. Raingeaud J, Whitmarsh AJ, Barrett T, Derijard B, Davis RJ. MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen activated protein kinase signal transduction pathway. Mol Cell Biol 1996; 16:1247-1255 (Pubitemid 26061695)
2. Armant MA, Fenton MJ. Toll-like receptors: a family of pattern-recognition receptors in mammals. Genome Biol 2002; 3:3011-3016
3. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001; 81:807-869 (Pubitemid 32267078)
4. Manthey CL, Wang SW, Kinney SD, Yao Z. SB202190, a selective inhibitor of p38 mitogen-activated protein kinase, is a powerful regulator of LPS-induced mRNAs in monocytes. J Leukoc Biol 1998; 64:409-417 (Pubitemid 28409249)
5. Lee JC, Kassis S, Kumar S, Badger A, Adams JL. p38 mitogenactivated protein kinase inhibitors-mechanisms and therapeutic potentials. Pharmacol Ther 1999; 82:389-397 (Pubitemid 29255932)
6. Saklatvala J, Dean J, Clark A. Control of the expression of inflammatory response genes. Biochem Soc Symp 2003; 70:95-106. (Pubitemid 38497218)
7. Hommes DW, Peppelenbosch MP, van Deventer SJH. Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets. Gut 2003; 52:144-151
8. Baldassare JJ, Bi Y, Bellone CJ. The role of p38 mitogenactivated protein kinase in IL-1 h transcription. J Immunol 1999; 162:5367-5373 (Pubitemid 29307144)
9. Saccani S, Pantano S, Natoli G. p38-dependent marking of inflammatory genes for increased NF-nB recruitment. Nat Immunol 2002; 3:69-71.
10. Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griswold DE. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 1996; 279:1453-1461 (Pubitemid 27166795)
11. Griswold DE, Young PR. Pharmacology of cytokine suppressive antiinflammatory drug binding protein (CSBP), a novel stress-induced kinase. Pharmacol Commun 1996; 7:323-329
12. Tong L, Pav S, White DM, Rogers S, Crane KM, Cywin CL, et al. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nat Struct Biol 1997; 4:311-316 (Pubitemid 27157204)
13. Hommes D, van den Blink B, Plasse T, Bartelsman J, Xu C, Macpherson B, et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002; 122:7-14. (Pubitemid 34049188)
14. Van der Blink B, Ten Hove T, Van der Brink GR, Peppelenbosch M, Van Deventer SJH. From extracellular to intracellular targets, inhibiting MAP kinases in treatment of Crohn's disease. Ann NY Acad Sci 2002; 973:349-358 (Pubitemid 36125034)
15. van Montfrans C, Peppelenbosch M, te Velde AA, van Deventer S. Inflammatory signal transduction in Crohn's disease and novel therapeutic approaches. Biochem Pharmacol 2002; 64:789-795
16. Kim JM, Jung HY, Lee JY, Youn J, Lee CH, Kim KH. Mitogen-activated protein kinase and activator protein-1 dependent signals are essential for Bacteroides fragilis enterotoxin-induced enteritis. Eur J Immunol 2005; 35:2648-2657 (Pubitemid 41404048)
17. Assi K, Pillai R, Gómez-Muñoz A, Owen D, Salh B. The specific JNK inhibitor SP600125 targets tumour necrosis factor-alpha production and epithelial cell apoptosis in acute murine colitis. Immunology 2006; 118:112-121
18. Scaldaferri F, Sans M, Vetrano S, Correale C, Arena V, Pagano N, et al. The role of MAPK in governing lymphocyte adhesion to and migration across the microvasculature in inflammatory bowel disease. Eur J Immunol 2009; 39:290-300.
19. Danese S. Nonimmune cells in inflammatory bowel disease: from victim to villain. Trends Immunol 2008; 29:555-564
20. Mayer RJ, Callahan JF. p38 MAP kinase inhibitors: a future therapy for inflammatory diseases. Drug Discov Today 2006; 3:49-54.
21. Hill RJ, Dabbagh K, Phippard D, Li C, Suttmann RT, Welch M, et al. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity. J Pharmacol Exp Ther 2008; 327:610-619
22. Cohen P. Targeting protein kinases for the development of anti-inflammatory drugs. Curr Opin Cell Biol 2009; 21:317-324